Technology designed around what the immune system actually sees
RIGHT TARGETS
Measured, not predicted
Our Precision Immunomics™ discovery pipeline integrates state-of-the art immunopeptidomcs, transcriptomoics and genomics, with AI/ML trained on data from real patient samples, to produce a best-in-class repertoire of shared, tumour-specific antigens identified.
We detect antigens from coding and ‘dark’ regions of the genome without bias, allowing us to select the best possible targets, regardless of the source. Shortlisted targets undergo rigorous biological validation to allow us to design de-risked, off-the-shelf vaccines, cancer type by cancer type.
Everything we see is a real target. Using immunopeptidomics, wedirectly read what tumours present to the immune system.
presentation
Most mutations are never processed, presented, or recognised by T cells so relying on prediction restricts the proportion of identified antigens that are therapeutically relevant.
RIGHT VECTORS
RIGHT PATIENTS,
RIGHT TIME
Our off-the-shelf approach allows us to investigate our precision vaccines alongside the standard of care for a given cancer type at any timepoint in a patient’s cancer treatment journey.
The accelerated regulatory route enabled by our MHRA-awarded Innovative Licensing and Access Pathway (ILAP) passport, has allowed us to initiate our first-in-human VISTA study: a randomised, placebo-controlled, double-blind phase 1/2a trial in resectable oesophageal adenocarcinoma. This is a population with high unmet need, with half of patients experiencing recurrence within 2-3 years of surgery.
VISTA is designed to provide rapid proof-of-concept for our Precision ImmunomicsTM antigen discovery platform and our proprietary vector platform. We are actively exploring partnership and collaboration opportunities to accelerate expansion into an initial 4 additional cancers covering a $45 billion addressable market.
